MedTrace Logo

Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)

NCT07035405 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 7500

Last updated 2025-06-27

No results posted yet for this study

Summary

The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.

Conditions

Interventions

DRUG

Colchicine 0.5 mg

Oral colchicine will be initiated with a dose of 0.5 mg per day.

DRUG

Placebo colchicine

Oral placebo colchicine will be initiated with a dose of 0.5 mg per day.

Sponsors & Collaborators

  • Shenzhen Medical Academy of Research and Translation

    collaborator UNKNOWN

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Yongjun Wang · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-04
Primary Completion
2028-12-31
Completion
2028-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07035405 on ClinicalTrials.gov